TNFAIP3 and esophageal squamous cell carcinoma: The expression of TNFAIP3 at both the protein and gene levels in ESCC‐TRCs treated with ZSH‐2208 showed a decreasing trend, as well as its binding protein TNIP1, with increasing doses of ZSH‐2208 (Figures 4I and S5I,J), which is consistent with the dose‐dependent inhibitory effect of ZSH‐2208 on RARγ observed in previous in vitro experiments.